Sharing Operational Insights for the Delivery of Bispecific Antibodies in Solid Tumor

Clinical data and research indicate that bispecific antibodies (BsAbs) have significant immunotherapeutic potential and may soon be available to treat solid tumors. This is exciting news for people living with small cell lung, prostate, gastrointestinal, and other cancers. Exploring the potential of BsAbs as treatment options for patients with solid tumors, the Association of Community Cancer Centers (ACCC) has proposed expanding upon its prior work, the hematologic malignancy-focused project "Using Bispecific Antibodies in Community Practice."

The goal of this project is to keep providers informed of the latest findings in solid tumor applications. By highlighting best practices and sharing written guidelines, ACCC hopes that when BsAbs therapy for solid tumors becomes available, care providers will feel confident administering the treatment in community and rural cancer programs.

For more information about this project, please contact the ACCC Provider Education Department.

This project is sponsored by Amgen; however, Amgen did not exert any editorial control on the content.